Full Breakdown
The Global Divide in Access to Keytruda: A Life-Saving Drug
4/13/2026, 7:47:04 PM
Overview of Keytruda's Impact and Accessibility
Keytruda (pembrolizumab), an immunotherapy drug developed by Merck & Co., has transformed cancer treatment since its approval in 2014. It is now recognized for extending survival for millions of patients across at least 19 types of tumors. However, a comprehensive investigation by Deutsche Welle and the International Consortium of Investigative Journalists (ICIJ) reveals a stark divide in access to this life-saving medication, driven by pricing strategies, patent protections, and regulatory frameworks.
The Financial Landscape of Keytruda
Keytruda has become one of the best-selling drugs globally, generating approximately $31.7 billion in sales in 2025 alone, with about 60% of revenue coming from the United States. Despite its success, the annual treatment costs range significantly, from $80,000 in Germany to $208,000 in the U.S., placing immense pressure on healthcare systems worldwide. In the UK, studies indicate that the National Health Service has overpaid for Keytruda, with costs reaching up to five times its assessed value in some cases.
Patent Strategies and Market Exclusivity
Merck's extensive use of the patent system has been pivotal in maintaining its market dominance. The investigation identified over 1,212 patent applications related to Keytruda across 53 jurisdictions, with primary patents set to expire in 2028 but follow-on patents potentially extending exclusivity until 2042. Critics argue this creates a "patent fortress" that delays the introduction of cheaper alternatives, while Merck contends that these filings reflect ongoing innovation.
Disparities in Access and Affordability
Access to Keytruda is heavily influenced by geographic and economic factors. In lower-income countries like India, treatment costs can exceed a patient's annual income, effectively restricting access to a small segment of the population. The investigation documented numerous cases where patients resorted to crowdfunding or legal action to obtain the drug. In Brazil, for instance, thousands of lawsuits have been filed as patients seek court-ordered access to treatment.
The Counterfeit Crisis
In India, a significant counterfeit drug racket has emerged, where desperate patients unknowingly purchased fake Keytruda at reduced prices. Investigations revealed that counterfeit versions were sold for as low as INR90,000 per vial, leading to tragic outcomes for patients who received ineffective treatments. The scandal highlights critical gaps in hospital systems and the urgent need for better monitoring and regulation.
Official Responses and Future Implications
Merck has defended its pricing strategy, asserting that it reflects the drug's value and the complexities of healthcare systems. The company has also pointed to its patient assistance programs and differential pricing strategies aimed at improving access in low- and middle-income countries. However, the investigation underscores a broader systemic issue within the pharmaceutical industry, where pricing strategies and patent protections often favor manufacturers over patients.
Conclusion: A Call for Equity in Healthcare
The findings from the ICIJ investigation raise profound questions about the nature of medical innovation and its accessibility. As disparities in access to Keytruda persist, the debate continues over whether medical advancements should be treated as a common good or a commercial asset. The urgent need for equitable healthcare solutions is evident, as the consequences of these disparities are felt by patients worldwide.
